anti-QARS antibody product blog
Tags: Antibody; Polyclonal Antibody; QARS; anti-QARS antibody;
The QARS qars (Catalog #MBS6012285) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. The QARS (Glutamine--tRNA Ligase, Glutaminyl-tRNA Synthetase, GlnRS) reacts with Human and may cross-react with other species as described in the data sheet. MyBioSource\'s QARS can be used in a range of immunoassay formats including, but not limited to, Western Blot (WB), Immunofluorescence (IF).Suitable for use in Immunofluorescence and Western Blot.
Dilution: Immunofluorescence: 10ug/ml. Researchers should empirically determine the suitability of the QARS qars for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
The QARS qars product has the following accession number(s) (GI #48257155) (NCBI Accession #AAH01772.2) (Uniprot Accession #P47897). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful. The amino acid sequence is listed below:
MAALDSLSLF TSLGLSEQKA RETLKNSALS AQLREAATQA QQTLGSTIDK ATGILLYGLA SRLRDTRRLS FLVSYIASKK IHTEPQLSAA LEYVRSHPLD PIDTVDFERE CGVGVIVTPE QIEEAVEAAI NRHRPQLLVE RYHFNMGLLM GEARAVLKWA DGKMIKNEVD MQVLHLLGPK LEADLEKKFK VAKARLEETD RRTAKDVVEN GETADQTLSL MEQLRGEALK FHKPGENYKT PGYVVTPHTM NLLKQHLEIT GGQVRTRFPP EPNGILHIGH AKAINFNFGY AKANNGICFL RFDDTNPEKE EAKFFTAICD MVAWLGYTPY KVTYASDYFD QLYAWAVELI RRGLAYVCHQ RGEELKGHNT LPSPWRDRPM EESLLLFEAM RKGKFSEGEA TLRMKLVMED GKMDPVAYRV KYTPHHRTGD KWCIYPTYDY THCLCDSIEH ITHSLCTKEF QARRSSYFWL CNALDVYCPV QWEYGRLNLH YAVVSKRKIL QLVATGAVRD WDDPRLFTLT ALRRRGFPPE AINNFCARVG VTVAQTTMEP HLLEACVRDV LNDTAPRAMA VLESLRVIIT NFPAAKSLDI QVPNFPADET KGFHQVPFAP IVFIERTDFK EEPEPGFKRL AWGQPVGLRH TGYVIELQHV VKGPSGCVES LEVTCRRADA GEKPKAFIHW VSQPLMCEVR LYERLFQHKN PEDPTEVPGG FLSDLNLASL HVVDAALVDC SVALAKPFDK FQFERLGYFS VDPDSHQGKL VFNRTVTLKE DPGKV.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Please refer to the product datasheet for known applications of a given antibody. We\'ve tested the QARS (Glutamine--tRNA Ligase, Glutaminyl-tRNA Synthetase, GlnRS) with the following immunoassay(s):
Western Blot (WB) (QARS polyclonal antibody. Western Blot analysis of QARS expression in human liver.)
Western Blot (WB) (Western Blot analysis of QARS expression in transfected 293T cell line by QARS polyclonal antibody. Lane 1: QARS transfected lysate (85.25kD). Lane 2: Non-transfected lysate.)
Immunofluorescence (IF) (Immunofluorescence of purified antibody to QARS on HeLa cell. [antibody concentration 10ug/ml])
Aminoacyl-tRNA synthetases catalyze the aminoacylation of tRNA by their cognate amino acid. Because of their central role in linking amino acids with nucleotide triplets contained in tRNAs, aminoacyl-tRNA synthetases are thought to be among the first proteins that appeared in evolution. In metazoans, 9 aminoacyl-tRNA synthetases specific for glutamine (gln), glutamic acid (glu), and 7 other amino acids are associated within a multienzyme complex. Although present in eukaryotes, glutaminyl-tRNA synthetase (QARS) is absent from many prokaryotes, mitochondria, and chloroplasts, in which Gln-tRNA(Gln) is formed by transamidation of the misacylated Glu-tRNA(Gln). Glutaminyl-tRNA synthetase belongs to the class-I aminoacyl-tRNA synthetase family.
Immunogen: Full length human QARS, aa1-775 (NP_005042.1). In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing QARS are readily searchable from our website. Different antibodies against the same target such as QARS may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.